Ophthalmic diagnostic device manufacture ObjectiVision can’t file amended claims for damages following a trial in a copyright and contract case against the University of Sydney, with a judge saying the school would be “severely prejudiced” if the new claims were allowed.
The publisher of The Daily Telegraph has won its bid to bring a defence of justification against claims by actor Geoffrey Rush that the newspaper defamed him in articles alleging the actor behaved “inappropriately” during a production of King Lear at the Sydney Theatre Company.
Cargill has won court approval to amend its pleading against Viterra to include details of a law firm meeting in which Viterra executives allegedly made assurances that there were no quality issues with its malt, more than two months into the trial over the $420 million sale of Viterra’s Joe White Maltings business to Cargill in 2013.
A barrister for a class action against Radio Rentals has told the Federal Court the company’s “strange” lease contracts may have been worded solely to avoid its obligations under the Uniform Consumer Credit Code.
A judge has given the green light to a settlement of seven class actions against ratings agency S&P Global over toxic financial products, saying despite an “extraordinarily large” litigation funding fee the deal was a “significant vindication” of group member claims.
TransUrban has agreed to release detailed traffic data for its toll roads in New South Wales in hopes of winning the ACCC’s blessing of its proposed acquisition of a majority stake in the $16.8 billion WestConnex highway project.
Mining giant BHP Billiton has reached a $50 million deal to settle the US class action over the 2015 dam failure at the Samarco mine in Brazil.
Iluka Resources has shot back at claims in a shareholder class action that it made misleading statements about projected sales volumes, saying the statements were accompanied by extensive disclaimers about its ability to predict future sales.
A New York politician who was one of the earliest supporters of President Donald Trump has been indicted on charges of insider trading related to his investments in Australian biotech firm Innate Immunotherapeutics.
The lead applicant in an investor class action against Fitch Ratings will get its hands on internal reports detailing why the agency assigned a Triple A rating to Sigma Finance Corporation ahead of its 2008 collapse, and whether it could have predicted the fall of the $27 billion investment fund.